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Psychogenic nonepileptic seizures (PNES) are diagnosed in approximately 30% of patients referred 
to tertiary care epilepsy centers. Little is known about the molecular pathology of PNES, much less 
about possible underlying genetic factors. We generated whole‑exome sequencing and whole‑genome 
genotyping data to identify rare, pathogenic (P) or likely pathogenic (LP) variants in 102 individuals 
with PNES and 448 individuals with focal (FE) or generalized (GE) epilepsy. Variants were classified for 
all individuals based on the ACMG‑AMP 2015 guidelines. For research purposes only, we considered 
genes associated with neurological or psychiatric disorders as candidate genes for PNES. We observe 
in this first genetic investigation of PNES that six (5.88%) individuals with PNES without coexistent 
epilepsy carry P/LP variants (deletions at 10q11.22‑q11.23, 10q23.1‑q23.2, distal 16p11.2, and 
17p13.3, and nonsynonymous variants in NSD1 and GABRA5). Notably, the burden of P/LP variants 
among the individuals with PNES was similar and not significantly different to the burden observed in 
the individuals with FE (3.05%) or GE (1.82%) (PNES vs. FE vs. GE (3 × 2 χ2), P = 0.30; PNES vs. epilepsy 
(2 × 2 χ2), P = 0.14). The presence of variants in genes associated with monogenic forms of neurological 
and psychiatric disorders in individuals with pneS shows that genetic factors are likely to play a role 
in PNES or its comorbidities in a subset of individuals. Future large‑scale genetic research studies are 
needed to further corroborate these interesting findings in PNES.
PNES is considered a multifactorial biopsychosocial  disorder1, that can coexist with  epilepsy2, and which has a 
broad range of comorbid neurological and psychiatric disorders. Major depression and anxiety disorders are the 
most common psychiatric comorbidities, both reported in ~ 50% of all individuals with  PNES3,4. PNES, epilepsy, 
and psychiatric disorders cluster in families with a positive family history of psychiatric disorders in 7–22% of 
all individuals with  PNES5,6 and a positive family history of epilepsy in 7–48% of all individuals with  PNES5–7. 
However, the upper ranges of the estimates for a positive family history of psychiatric disorders and epilepsy are 
driven by the inclusion of individuals with PNES and comorbid epilepsy. Such individuals were not routinely 
excluded in the majority of all PNES studies.
Recent results indicate that some genetic risk factors are shared between common neurological and psychiat-
ric disorders (including epilepsy, depression, anxiety, and neuroticism)8,9 and may explain part of the observed 
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phenotypic  overlap10. Widespread pleiotropy for genes associated with Mendelian forms of neurological and 
psychiatric disorders suggests that these disorders are the response of a complex neurologic network, which is 
altered in several domains of function. For example, individuals affected by pathogenic variants in well-estab-
lished epilepsy genes usually have additional neurological or psychiatric  comorbidities11. While recent success 
in genetic studies has led to the identification of disease-associated genetic factors for virtually all disorders 
comorbid with PNES (i.e., anxiety, bipolar disorder, depression, epilepsy, intellectual disability, migraine, mood 
disorders, personality disorders, post-traumatic stress disorder, and schizophrenia), a genetic basis of PNES has 
been  speculated12, but never formally investigated.
To characterize genetically the heterogeneous phenotypic spectrum of individuals referred to a tertiary care 
center—we genotyped and sequenced 550 individuals with PNES or epilepsy, from the Cleveland Clinic Epilepsy 
Center, while excluding individuals with both PNES and epilepsy. We then selected all copy-number (CNVs) 
and single nucleotide variants (SNVs) with strong computational support for a deleterious effect on the involved 
gene/s and classified them according to the American College of Medical Genetics and Genomics and the 
Association for Molecular Pathology (ACMG-AMP) 2015  guidelines13. The guidelines require an established 
gene to phenotype association as one criterion for pathogenicity prediction. Because the genetic basis of PNES 
is unknown and no established PNES genes exist, we applied the ACMG-AMP guidelines for research purposes 
only and considered genes associated with neurological or psychiatric disorders as candidate genes for PNES. 
Our overall study design is presented in Fig. 1.
Figure 1.  Study design and execution. SNV: single nucleotide variant, CNV: copy number variant, WES: whole-
exome sequencing, QC: quality control, PCA: principal component analysis, FE: focal epilepsy, GE: generalized 
epilepsy, PNES: psychogenic nonepileptic seizures.
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Results
Cohort and analysis overview. We generated genotyping as well as exome data for 694 individuals ascer-
tained through the Epilepsy Biorepository of the Cleveland Clinic Epilepsy Center. The data was used to perform 
genome-wide CNV and whole-exome SNV analyses. After data quality control, 550 individuals with epilepsy or 
PNES were included in the downstream analyses (Table 1). The most prevalent diagnosis was focal epilepsy (FE, 
N = 393, 71.5%) followed by psychogenic nonepileptic seizures without epilepsy (PNES, N = 102, 18.5%), and 
generalized epilepsy (GE, N = 55, 10%).
Individuals in this study were 40 years old on average (standard deviation, SD = 15) and completed approxi-
mately 14 years of education (SD = 2). Fifty-three percent of the cohort was female and all of genetically defined 
European ancestry. The three study groups were well matched in terms of age and education. There were more 
females in the PNES group (75%) than in the epilepsy groups (FE: 47%, GE: 56%). The PNES group showed the 
highest proportion of individuals with comorbid psychiatric disorders or a history of chronic pain compared to 
the two epilepsy groups (Table 1). Individuals with FE were less likely to have a family history of epilepsy, defined 
as seizures in a first- or second-degree relative than those with GE (χ2 = 7.70, P = 0.006) or PNES (χ2 = 6.22, 
P = 0.013). However, the family history of seizures was similar between individuals with GE and PNES (χ2 = 0.402, 
P = 0.526). The percentage of individuals with comorbidities and a family history of seizures was similar between 
females and males with PNES (Supplementary Table 4).
Individuals with PNES carry pathogenic and likely pathogenic variants similar to individuals 
with epilepsy. Rare genetic variants are well-established risk factors associated with  epilepsy14. We first 
examined if individuals with PNES carry deleterious genetic variants, as classified by state-of-the-art in silico 
prediction methods. The results were compared to the control group of 448 individuals with epilepsy from the 
same epilepsy clinic. Identified potential deleterious insertion/deletion polymorphisms (indels, N = 56) did not 
survive our strict criteria for the visual inspection of the reads supporting each variant and were excluded from 
subsequent analyses. After data quality control and stringent variant filtering, we identified deleterious variants 
in 8.65% of all individuals with FE (N = 34, Supplementary Table 1), 10.91% of all individuals with GE (N = 6, 
Supplementary Table 2), and in 11.76% of all individuals with PNES (N = 12, Table 2) (Fig. 2). The proportions 
of individuals carrying only a specific variant type (single nucleotide or copy number variants) are displayed in 
Supplementary Figures 1 and 2. The deleterious variant burden across the three disorder types was not signifi-
cantly different (PNES vs. FE vs. GE, two-tailed 3 × 2 χ2, P = 0.59; PNES vs. epilepsy, two-tailed 2 × 2 χ2, P = 0.38).
Next, we classified all deleterious variants according to the ACMG-AMP 2015 guidelines to determine if 
individuals with PNES carry ACMG-AMP-classified pathogenic (P) or likely pathogenic (LP) genetic variants 
in genes associated with neurological disorders, and/or psychiatric disorders, including epilepsy. We found P/
LP variants in 3.05% of all individuals with FE (N = 12, Supplementary Table 1), 1.82% of all individuals with 
GE (N = 1, Supplementary Table 2), and in 5.88% of all individuals with PNES (N = 6, Table 2) (Fig. 2). The P/
LP variant burden across the three disorder types was not significantly different (PNES vs. FE vs. GE, two-tailed 
3 × 2 χ2, P = 0.30; PNES vs. epilepsy, two-tailed 2 × 2 χ2, P = 0.14). We also identified ACMG-AMG variants of 
uncertain significance (VUS) in 5.60% of all individuals with FE (N = 22, Supplementary Table 1), 9.09% of all 
individuals with GE (N = 5, Supplementary Table 2), and in 5.88% of all individuals with PNES (N = 6, Table 2) 
(Fig. 2). Out of all six P/LP variant carriers with PNES, one (16.7%) reported a family history of seizures, and two 
(33.3%) a family history of psychiatric disorders (anxiety, mood disorders, and post-traumatic stress disorder).
Table 1.  Demographic and clinical features of the 550 tertiary care epilepsy center patients. PNES: 
psychogenic nonepileptic seizures, FE: focal epilepsy, GE: generalized epilepsy, M: sample mean, SD: standard 
deviation, F/χ2: test statistic, P: P-value, N: number of individuals, PTSD: post-traumatic stress disorder.
PNES FE GE
F/χ2 P
N = 102 N = 393 N = 55
M (SD) M (SD) M (SD)
Age 42.5 (14.3) 39.7 (14.8) 38.2 (15.0) 2.03 0.133
Education 13.7 (2.4) 13.9 (2.5) 14.1 (2.2) 0.51 0.602
PNES FE GE
F/χ2 P
N = 102 N = 393 N = 55
N (%) N (%) N (%)
Sex (female) 76 (74.5%) 183 (46.6%) 31 (56.4%) 25.7  < 0.001
Comorbidities and family history
Depression 64 (62.7%) 164 (41.7%) 30 (54.5%) 15.8  < 0.001
Anxiety 54 (52.9%) 106 (27.0%) 25 (45.5%) 28.3  < 0.001
Bipolar disorder 11 (10.8%) 1 (1.8%) 1 (1.8%) 20.2  < 0.001
PTSD 14 (13.7) 5 (1.3%) 1 (1.8%) 36.4  < 0.001
Chronic pain 18 (17.6%) 23 (5.9%) 4 (7.3%) 15.1 0.001
Family history of seizures 32 (31.4%) 78 (19.8%) 20 (36.4%) 11.4 0.003
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Detailed evaluation of the deleterious variants found in individuals with PNES. We are una-
ware of any studies to date that have conducted genetic testing in individuals with PNES. Subsequently, there are 
no genes or variants that have been associated with PNES. Variant pathogenicity classification requires an estab-
lished gene-phenotype  association13. For research purposes, we classified variants in our sample of individuals 
with PNES as if the variants would have been identified in individuals with neurologic or psychiatric disorders. 
As a consequence, variants in genes associated with neuropsychiatric disorders could qualify for pathogenicity 
if additional variant level criteria were fulfilled.
The phenotypic characteristics of all deleterious variant carriers with PNES are listed in Table 3 and Supple-
mentary Tables 5 and 6. Six individuals with PNES were affected by P/LP variants (three males and three females). 
These variants included four CNVs and two missense variants (Table 2). Three out of the six P/LP variants were 
found to be known epilepsy-associated CNVs (deletions at 10q23.1-q23.2, distal 16p11.2, and 17p13.3). Deletions 
at 10q23.1-q23.2 are associated with complex genetic neurodevelopmental  syndromes15. Our patient with PNES 
and the 10q23.1-q23.2 deletion had normal neurodevelopment, an onset of PNES at 33 years of age, a history 
of migraine, chronic pain and mood disorder, and no history of febrile seizures or family history of seizures.
Deletions and duplications at distal 16p11.2 locus are associated with epilepsy, autism spectrum disorder, 
schizophrenia, lower IQ, and subcortical brain  abnormalities16. Our patient with PNES and the distal 16p11.2 
deletion had normal neurodevelopment, an onset of PNES at 55 years of age, and no history of febrile seizures 
or a family history of seizures. The third epilepsy-associated variant in PNES was a PAFAH1B1 gene disrupting 
17p13.3 deletion. PAFAH1B1 is a well-established gene for lissencephaly with seizures as the core symptom of 
this  disorder17. The 17p13.3 deletion also disrupts the gene METTL16. However, METTL16 is not associated with 
any disease and is unlikely to play a role in PNES causation, because METTL16 is known to tolerate missense 
(missense Z-score = 2.35) and loss-of-function variants (pLI = 0.61)18. Our patient with PNES and deletion of 
PAFAH1B1 had normal neurodevelopment, an onset of PNES at 30 years of age, a history of anxiety and post-
traumatic stress disorder (PTSD), and no history of febrile seizures or family history of seizures.
The next three P/LP variants (one P, two LP) were identified in two genes and at a chromosomal position, 
each implicated in neurological or psychiatric disorders with or without seizures (NSD1, 10q11.22-q11.23 dele-
tion, and GABRA5; Table 2). Heterozygous mutations in the NSD1 gene are associated with Sotos syndrome 
Table 2.  Pathogenic, likely pathogenic, and variants of uncertain significance in individuals with PNES. Chr: 
chromosome, GRCh37: Genome Reference Consortium Human Build 37, Mis_z: Z-score for missense variant 
intolerance of a gene, pLI: probability for the loss-of-function variant intolerance of a gene, Mb: mega base 
pairs, Kb: kilo base pairs, CN: copy number. a Exon numbers based on transcript NM_020204. b Exon numbers 
based on transcript NM_001282680.
ID Variant type Gene/s
Associated 
neurological/
psychiatric 
disorder
ACMG-AMP 
classification CytoBand Chr Start GRCh37 Stop GRCh37
Consequence/
nucleotide 
change/affected 
exon Mis_z pLI
PNES1 1.58 Mb dele-tion 7 genes Epilepsy Pathogenic 10q23.1-q23.2 10 87,136,787 88,718,934 CN loss – –
PNES2 218 Kb deletion 9 genes Epilepsy Pathogenic distal 16p11.2 16 28,826,049 29,044,745 CN loss – –
PNES3 229 Kb deletion PAFAH1B1, METTL16 Epilepsy Pathogenic 17p13.3 17 2,341,350 2,570,479 CN loss – –
PNES4 Nonsynony-mous SNV NSD1
Neurological/
psychiatric
Likely patho-
genic 5q35.3 5 176,720,953 176,720,953
p.Lys1926Arg 
(exon 23 out 
of 23)
3.70 1.00
PNES5 4.91 Mb Dele-tion 39 genes
Neurological/
psychiatric Pathogenic
10q11.22-
q11.23 10 46,943,377 51,856,375 CN loss – –
PNES6 Nonsynony-mous SNV GABRA5
Neurological/
psychiatric
Likely patho-
genic 15q12 15 27,188,485 27,188,485
p.Ala334Gly 
(exon 10 out 
of 11)
3.31 0.88
PNES7 Stopgain SNV LHX9 NA Uncertain significance 1q31.3 1 197,896,819 197,896,819
p.Gln269Ter 
(exon 4 out 
of 5)a
1.13 0.98
PNES8 Nonsynony-mous SNV MAPKAPK2 NA
Uncertain 
significance 1q32.1 1 206,904,045 206,904,045
p.Leu235Pro 
(exon 6 out 
of 10)
3.10 1.00
PNES9 Splicing SNV CAMKV NA Uncertain significance 3p21.31 3 49,899,726 49,899,726
c.95+1G>A 
(exon 2 out 
of 11)
3.39 1.00
PNES10 Stopgain SNV GAPVD1 NA Uncertain significance 9q33.3 9 128,118,066 128,118,066
p.Arg1319Ter 
(exon 25 out of 
28) b
2.75 1.00
PNES11 Nonsynony-mous SNV PRPF8 NA
Uncertain 
significance 17p13.3 17 1,579,337 1,579,337
p.Arg855Pro 
(exon 18 out 
of 43)
8.55 1.00
PNES12 Splicing SNV MYH9 NA Uncertain significance 22q12.3 22 36,717,867 36,717,867
c.706-1G>C 
(exon 7 out 
of 41)
3.67 1.00
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(autosomal dominant)19. Sotos syndrome is characterized by distinctive facial features, intellectual disability (ID), 
and overgrowth or macrocephaly, and seizures are reported in 9–50% of  cases20. Our patient with PNES and an 
NSD1 mutation had normal neurodevelopment, an onset of PNES at 12 years of age, a history of mood disorder, 
and no history of febrile seizures or family history of seizures. Deletions and duplications at 10q11.22-q11.23 
are associated with developmental delay or  ID21. Our patient with PNES and the 10q11.22-q11.23 deletion had 
normal neurodevelopment, an onset of PNES at 50 years of age, a history of mood disorder and anxiety, no his-
tory of febrile seizures, and a suggestive family history of seizures (affected aunt). Finally, GABRA5 is a candidate 
gene for epilepsy and developmental  delay22, which has not yet been statistically associated with epilepsy through 
an exome-wide cohort screen. Our patient with PNES and a GABRA5 mutation had normal neurodevelopment, 
an onset of PNES at 40 years of age, a history of mood disorder, anxiety, and PTSD, and no history of febrile 
seizures or family history of seizures.
Out of the six identified VUS, four were identified in genes with a potential role in brain function (LHX9, 
MAPKAPK2, CAMKV, and MYH9). Expression of LHX9 was shown to be repressed by kainic acid-induced 
 seizures23, while MAPKAPK2 expression was  induced24. CAMKV encodes for a synaptic protein crucial for den-
dritic spine  maintenance25. Heterozygous mutations in MYH9 are associated with a spectrum of autosomal domi-
nant  thrombocytopenias26. The most devastating consequence of thrombocytopenia is intracranial hemorrhage, 
and one case with recurrent seizures related to intracranial hemorrhage was recently described in the  literature27.
Discussion
We generated whole-exome sequencing and whole-genome genotyping data to identify rare, P/LP variants in 
a cohort of 550 individuals with PNES or epilepsy (focal or generalized). This study represents the first genetic 
investigation of PNES. We used the ACMG-AMP 2015  guidelines13 to classify variants from the perspective of 
Mendelian forms of neurological or psychiatric disorders, including epilepsy. We show that P/LP variants in 
genes implicated in a broad range of neurological and psychiatric disorders are found in individuals with PNES 
evaluated in a tertiary care epilepsy center. Interestingly, we did not observe a significant difference in the bur-
den of P/LP variants, when comparing individuals with PNES without coexistent epilepsy to individuals with 
epilepsy. The observed variant burden is not surprising for the epilepsies, and elevated burdens of CNVs or SNVs 
have been observed in several large-scale studies that compared individuals with epilepsy against population 
 controls11,14,28,29. In contrast, genetic factors have not been previously identified for PNES.
We executed a very stringent state-of-the-art variant filtering strategy, optimized for high specificity to identify 
deleterious SNVs. Following evidence from large-scale studies in epilepsy and other neurological disorders show-
ing that most of the causal variants are ultra-rare in the general  population14,30, we only selected and classified 
unique SNVs not seen in > 200 k population controls. We only considered CNVs if the locus had previously been 
associated with neurological or psychiatric disorders. The goal of this strategy was to prioritize genetic variants 
that have a high likelihood to be true and pathogenic for a robust comparison of the PNES and epilepsy groups. 
Future studies will have to balance sensitivity vs. specificity to prioritize variant discovery.
Figure 2.  Burden of pathogenic and likely pathogenic SNVs and CNVs in individuals with FE, GE, or PNES. 
Each stacked bar plot represents the total percentage of carriers of (i) pathogenic variants, highlighted in blue; 
(ii) likely pathogenic variants, highlighted in light blue; and (iii) variants of uncertain significance, highlighted 
in green. The classification of the variants in the individuals with PNES was performed for research purposes 
only. FE: focal epilepsy, GE: generalized epilepsy, PNES: psychogenic nonepileptic seizures, N: number of 
individuals with each phenotype.
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Among the 12 deleterious variants identified in individuals with PNES without coexistent epilepsy, 50% (6/12) 
were classified according to the ACMG-AMP 2015 guidelines as pathogenic or likely pathogenic. The ACMG-
AMP 2015 guidelines require an established gene to phenotype association as one criterion for pathogenicity 
 prediction13. In a clinical setting, the same variants would not be classified as pathogenic since no single estab-
lished PNES gene exists. Nevertheless, the detection of pathogenic variants that are likely to cause Mendelian 
forms of neurological or psychiatric disorders in individuals with PNES is in line with emerging evidence that 
neurological or psychiatric disorders share a broad range of pleiotropic acting genetic  variation8,11,31. Our results 
are also in line with the observation that up to 48% of all individuals with PNES report a family history of epi-
lepsy and 22% a family history of psychiatric  disorders6. PNES could represent one of several clinically defined 
phenotypes associated with pleiotropic acting genetic variants, affecting genes essential for brain development 
and function. Surprisingly, none of the P/PL variant carriers with PNES had an abnormal bedside cognition/neu-
rological examination or any major structural abnormality on MRI. However, formal neuropsychological testing 
was not performed; therefore, it is possible that individuals had more subtle forms of cognitive impairment. It 
is also possible that our results represent phenotype expansions for some of the genes affected by P/PL variants. 
Phenotype expansions are common as shown for SLC6A1, a known gene for autism spectrum disorders, epilepsy, 
and  ID32, which was recently associated with schizophrenia without ID or other neurodevelopmental  disorder33. 
Finally, despite an ACMG-AMP 2015 guidelines classification as VUS, we cannot exclude the involvement of the 
six identified VUS in PNES causation, as all variants identified in this study were predicted in silico as highly 
pathogenic, never seen in the general population, and affected highly variant intolerant genes. Future case/control 
studies are needed to identify genes that have not been implicated in other disorders as associated with PNES.
The four identified deletions in individuals with PNES in this study have been reported in the literature in 
epilepsy and other neurological disorders, with high phenotypic variability and incomplete  penetrance15,16,21,34. 
This high degree of pleiotropy has been observed for the vast majority of all deletions that have been associated 
with epilepsy or other neurological  disorders35. Most likely, these deletions impair neurodevelopmental processes 
Table 3.  Phenotypic characteristics of individuals with PNES and deleterious genetic variants. HTN: 
hypertension, DM: diabetes mellitus, HPL: hyperlipidemia, COPD: chronic obstructive pulmonary disease, 
CAD: coronary artery disease, CHF: congestive heart failure, CKD: chronic kidney disease, OSA: obstructive 
sleep apnea, PTSD: post-traumatic stress disorder, Mood Disorder: depression or bipolar disorder, CVD: 
cerebrovascular disease, PGF: paternal grandfather, PCOS: polycystic ovarian syndrome, OCD: obsessive–
compulsive disorder, MGF: maternal grandfather, MGM: maternal grandmother, IBS: irritable bowel 
syndrome.
ID Sex
Identified 
variant 
(ACMG-AMP 
classification) Age
Age at PNES 
onset
Cognition/
neuro exam MRI
Febrile 
seizures
Medical 
comorbidities
Psychiatric 
comorbidities
FH of 
seizures
FH of 
psychiatric 
disease
PNES1 Male Pathogenic 33 33 Normal/nor-mal Normal No
Migraine, 
chronic pain Mood disorder No No
PNES2 Male Pathogenic 59 55 Normal/nor-mal Normal No
HTN, DM, 
HPL, COPD, 
OSA, CAD/
CHF, CKD
None No No
PNES3 Female Pathogenic 33 30 Normal/nor-mal Unknown No None Anxiety, PTSD No
Yes—PTSD, 
anxiety
PNES4 Male Likely patho-genic 58 12
Normal/nor-
mal Normal No HTN, OSA Mood disorder No No
PNES5 Female Pathogenic 50 50 Normal/nor-mal Normal No
Hypothyroid-
ism
Mood disor-
der, anxiety Yes—aunt
Yes—mood 
disorder
PNES6 Female Likely patho-genic 45 40
Normal/nor-
mal Normal No
HTN, HPL, 
CAD, CVD
Mood disor-
der, anxiety, 
PTSD
No No
PNES7 Female Uncertain significance 39 34
Normal/nor-
mal Normal No
Migraine, 
HTN, DM, 
OSA, PCOS, 
optic neuritis
Mood disor-
der, anxiety No
Yes—mood 
disorder, OCD
PNES8 Female Uncertain significance 50 50
Normal/nor-
mal Normal No Migraine, HPL Anxiety No No
PNES9 Female Uncertain significance 48 28
Normal/nor-
mal
Mild chronic 
microvascular 
disease
No DM, OSA, IBS, CVD
Mood disor-
der, anxiety No No
PNES10 Female Uncertain significance 43 7
Normal/nor-
mal
Mild chronic 
microvascular 
disease
No
Migraine, DM, 
CKD, OSA, 
hypothyroid-
ism
Mood disor-
der, anxiety Yes—MGM No
PNES11 Female Uncertain significance 26 15
Normal/nor-
mal Normal No
Migraine, 
chronic pain
Mood disor-
der, anxiety, 
PTSD
Yes—MGF
Yes—mood 
disorder, 
anxiety
PNES12 Male Uncertain significance 53 51
Normal/nor-
mal Normal No None Mood disorder Yes—mother No
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in a rather nonspecific manner and contribute to the genetic variance of a broad spectrum of neurological disor-
ders. The specific disease phenotype is likely further specified by the interplay with genetic background effects 
and environmental influences following an oligo-/polygenic inheritance model with substantial genetic hetero-
geneity. Environmental factors which predispose to PNES are very well  established1. Genetic vulnerability for a 
neurological or psychiatric condition could predispose to PNES when combined with environmental stressors. 
Individual differences in the genetic vulnerability to specific types of trauma and other environmentally relevant 
variables have been demonstrated, for example, for  PTSD36,37. In our study, the P/LP variant carriers showed 
a similar rate of presence/absence of a history of trauma or abuse as individuals with PNES and no identified 
variants (P/LP carriers: 3/3 vs. no variants identified: 30/25). However, more research is needed to support this 
hypothesis and to explain our observation that individuals with PNES alone can carry pathogenic variants that 
affect genes linked to clinically severe phenotypes.
In conclusion, in this report, we provide the first evidence that genetic factors may play a role in the etiol-
ogy of PNES. Future large-scale projects that employ comprehensive genetic testing, including polygenic risk 
scores, are needed for PNES and related genetically understudied disorders such as PTSD, and other conversion 
disorders. Potentially, such work could provide clues to the etiology and pathophysiology of the disorder, enable 
the identification of disease biomarkers, and set new directions for the development of new therapies for PNES.
Material and methods
Study participants. Data for this study were obtained from a Cleveland Clinic Institutional Review Board-
approved epilepsy biorepository. All methods were performed in accordance with relevant guidelines and regu-
lations regarding research involving human subjects. All participants provided written, informed consent, and a 
blood or saliva sample for use in medical/genetic research. Participants were selected for study inclusion if they 
met the following criteria: (1) age 18 years or older, (2) video-EEG confirmed diagnosis of focal epilepsy (FE), 
generalized epilepsy (GE), or psychogenic nonepileptic seizures (PNES) without comorbid epileptic seizures, 
and (3) had blood or saliva DNA available for whole-exome sequencing (N = 694). Our study cohort is detailed 
in Fig. 1.
Phenotyping procedures. Initial medical record review was conducted for all potential study participants 
by an epilepsy biorepository research coordinator trained in clinical epilepsy phenotyping (L.F.) and supervised 
by clinical epileptologists (J.F.B., L.J.). Diagnoses of epilepsy or PNES were established after review of the history 
and physical examination, scalp EEG video evaluation report, progress notes, social work, psychology and/or 
psychiatry report, and discharge summary as well as other documentation pertinent to the medical history and 
clinical diagnoses. Psychiatric diagnoses were established through review of the medical records and patient 
self-reports during the video-EEG admission. Individuals were classified as having FE, GE, or PNES based on 
video-EEG and concordant history. All individuals classified as PNES on initial review were re-reviewed by a 
clinical epileptologist (J.F.B.) to confirm the diagnosis. The diagnosis of PNES required video-EEG recording of 
a semiology typical for PNES, and an absence of epileptiform abnormalities on either interictal or ictal  EEG38. 
Accordingly, all individuals with PNES included in this study had video-EEG diagnosed PNES without comor-
bid epilepsy. Individuals with episodes explained by another diagnosis such as physiologic nonepileptic events 
(e.g., syncope, migraine, sleep disorder) were excluded from the study as were those with comorbid PNES and 
epileptic seizures and those with episodes consisting of purely subjective symptoms without objective signs (to 
prevent the inclusion of individuals with epileptic auras, which often do not have EEG abnormalities).
Copy number calling. A total of 688,032 single nucleotide polymorphisms (SNPs) were genotyped for all 
samples of this study using the Global Screening Array with Multi-disease drop-in (GSA-MD v1.0) (Illumina, 
San Diego, CA, USA). The SNP-data was used to detect CNVs in our dataset, using PennCNV’s copy number 
variant (CNV) calling  algorithm39 with GC-wave adjustment. We generated a custom population B-allele fre-
quency (BAF) file before calling CNVs. Adjacent CNVs were merged if the number of intervening markers 
between them was less than 20% of the total number of the whole segment encompassing both CNVs. CNV call-
ing was followed by extensive quality control (QC) for both samples and CNVs, respectively. Samples with signal 
intensity log R Ratio (LRR) standard deviation < 0.23, variability of the average LRR values in sliding windows 
(waviness factor, WF) < 0.02, departure of the BAF from the expected values for two copies (BAF drift) < 0.003, 
total numbers of CNVs < 80, and European ancestry were included in the analysis. CNV calls were removed 
from the dataset if they spanned less than 20 markers, were less than 20 Kb in length, had a marker density 
(amount of markers/length of CNV) < 0.0001, overlapped by > 50% of their total length with regions known to 
generate  artifacts40, or had a frequency > 1% in the study sample. CNVs that were spanning more than 20 mark-
ers over ≥ 1 Mb were included in the analysis, even if the marker density was < 0.0001. All CNVs of interest were 
examined visually by plotting the signal intensities using  PennCNV39 (Supplementary Figures 3–9).
Whole‑exome sequencing. Whole-exome sequencing (WES) of all samples in this study was performed 
using Nextera Rapid Capture Exomes enrichment and paired-end reads (151 bp) Illumina sequencing on the 
Illumina HiSeq 4,000. Duplicate read removal, format conversion, and indexing of the reads, aligned to the 
GRCh37 human genome reference (RefSeq: GCF_000001405.13), were performed using Picard (https ://broad 
insti tute.githu b.io/picar d). All samples were jointly called using the Genome Analysis Toolkit (GATK) best prac-
tice  pipeline41.
WES quality control. Quality control (QC) was performed in two iterations of a sample- and variant-level 
quality filtering. Sequencing and alignment quality metrics were computed using Picard tools (https ://broad 
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insti tute.githu b.io/picar d/), leading to the exclusion of samples with freemix contamination estimates > 0.02 and 
excess chimeric reads > 1%. Low quality variants were filtered out based on the following criteria: (i) phred 
quality score, QUAL < 20; (ii) GATK truth sensitivity tranche > 99.5% for single nucleotide variants (SNVs) 
and > 95% for indels; (iii) > 2 alleles; (iv) inbreeding coefficient < − 0.2; (v) sample read depth (DP) for SNVs < 20 
and for indels < 30; (vi) genotype quality (GQ) < 99; (vii) allelic balance of heterozygous SNV < 0.25, homozy-
gous SNV < 0.9, heterozygous indels < 0.30, and homozygous indels < 0.95. At the individual level, we removed 
related samples  (KING42 kinship coefficient > 0.0442), samples not clustering with the 1,000 Genomes Project 
European-ancestry samples (GCTA 43 principal component analysis), and samples with ambiguous sex or mis-
match with the reported gender. We also filtered out samples that exceeded three standard deviations (SD) from 
the mean of the entire study cohort on any of the following WES metrics: (i) low mean DP; (ii) low singleton 
count; (iii) low SNV count; (iv) low or high singleton/SNV ratio; (v) low transition/transversion ratio; (vi) low or 
high heterozygous/homozygous variant ratio; and (vii) low or high insertion/deletion ratio. Finally, we applied 
the following exclusion thresholds for variants in the samples that survived previous QC filtering: (i) geno-
type call rate < 0.95; (ii) minor allele frequency > 0.1; (iii) deviation from the Hardy–Weinberg equilibrium with 
P < 1 × 10–20. The supporting aligned reads of all variants that survived filtering for deleteriousness, detailed in 
the following paragraph, were visually inspected using the IGV  browser44.
Variant deleteriousness assessment. We applied for the identified CNVs and SNVs two different strat-
egies to assess the likelihood of a deleterious effect on disease-relevant loci or genes. CNVs: We only consid-
ered CNVs as deleterious if the locus had previously been associated with neurological or psychiatric disorders. 
SNVs: We used  ANNOVAR45 with custom databases to perform a state-of-the-art variant annotation for sub-
sequent deleteriousness assessment. We applied two different filters, based on: i) variant type and frequency 
and (ii) predicted variant deleteriousness. The frequency-based filter was based on the following criteria: (i) 
variant not in a genomic duplication (> 1,000 bases of non-repeat masked sequence); (ii) not present in multi-
ple variant databases, totaling > 200 k population controls (Supplementary Table 3). From the remaining vari-
ants, we selected only variants with a high confidence prediction to be deleterious using following criteria: (i) 
loss-of-function (LoF) variants ranked in the top 1% most deleterious variants in the human genome (scaled 
CADD ≥ 20)46 found in known epilepsy genes or highly LoF-intolerant  genes18 (probability, pLI ≥ 0.95); (ii) mis-
sense variants ranked in the top 1% most deleterious variants in the human genome (scaled CADD ≥ 20)46 found 
in missense-constrained regions (MPC ≥ 2 and MTR centile < 15%)47,48, of epilepsy genes or missense intolerant 
genes (missense Z-score > 3.09, corresponding to P < 10–3)18.
ACMG‑AMP 2015 classification of the deleterious CNVs and SNVs. The pathogenicity of all delete-
rious SNVs was assessed according to the ACMG-AMP  guidelines13 using  InterVar49. We adjusted the InterVar 
interpretations were needed for: (i) variant type in genes with a known mode of inheritance; (ii) location of the 
variant in protein; (iii) absence of variant in population controls; (iv) known gene function and association with 
disease. Deleterious SNVs expected to cause disorders that are not neurological or psychiatric (i.e., incidental 
findings), were considered as variants of uncertain significance. The pathogenicity of all deleterious CNVs was 
assessed directly, using the ACMG-AMP criterions PVS1, PS1, and  PS413, when supported by definite evidence.
Data availability
Data are available from the corresponding authors on reasonable request.
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